We have previously demonstrated that overexpression of dihydrodiol dehydrogenase isoform 1 (DDH1) or DDH2 leads to the induction of drug resistance to platinum based drugs in human ovarian, lung, cervical and germ cell tumor cell lines. DDH belongs to a family of aldoketo reductases that are involved in the detoxiWcation of several endogenous and exogenous substrates. DDH1 and DDH2 in particular have been shown to be involved in the detoxiWcation (activation?) of polycyclic aromatic hydrocarbons (PAH). Based on the involvement of DDH in the detoxiWcation of electrophilic PAH intermediates, the eVect of DDH on the production of reactive oxygen species (ROS) in a cisplatin-sensitive and -resistant human ovarian carcinoma cell line was investigated in the current study. In addition to the overexpression of DDH1 and DDH2, to an increase in the basal levels of ROS production (although transfection of siRNA against DDH3 resulted in cell death). The 2008/C13* cells were found to be crossresistant to the cytotoxic eVects of hydrogen peroxide and tert-butyl hydroperoxide and knockdown of either DDH1 or DDH2 expression (using siRNA) resulted in sensitization of the resistant cells to these agents. These results support the conclusion that the increased levels of DDH in the 2008/C13* cells are directly responsible for the reduced production of ROS and that this may play a role in the development of cisplatin resistance.
ROS level as compared to the 2008 cells and ROS production was decreased in the recombinant 2008 cells with forced, constitutive overexpression of either, DDH1, DDH2, or DDH3. Transfection of siRNA against DDH1 or DDH2 in the cisplatin-resistant 2008/C13* cells not only signiWcantly decreased their cisplatin-resistance index (as assayed by MTT and colony formation assay) but also led to an increase in the basal levels of ROS production (although transfection of siRNA against DDH3 resulted in cell death). The 2008/C13* cells were found to be crossresistant to the cytotoxic eVects of hydrogen peroxide and tert-butyl hydroperoxide and knockdown of either DDH1 or DDH2 expression (using siRNA) resulted in sensitization of the resistant cells to these agents. These results supof tumor cell resistance subsequent to drug treatment [32] . In order to decipher the mechanisms of cisplatin resistance, the human ovarian carcinoma cell line (2008) and its cisplatin-resistant variant (2008/C13*) have been utilized. Several biochemical alterations thought to be associated with cisplatin resistance have been identiWed in the 2008/ C13* cells. Previous work in our and other laboratories has demonstrated that the 2008/C13* cells exhibit a decreased intracellular accumulation of cisplatin [1] , increased replicative bypass of cisplatin-DNA adducts [17] , reduced expression of membrane-associated -tubulin [6] , and decreased expression of the intermediate Wlament, cytokeratin 18 [24] . Moreover, the mitochondria in the 2008/C13* appear morphologically aberrant and these cells are hypersensitive to lipophilic cations as compared to the parental cells [2] . Variations in the activation of protein kinase C activity [14] and in the cAMP signal transduction pathway [18] have also been observed in 2008/C13* cells. An increased level of expression of the oncogene c-fos in the 2008/C13* cells has recently been reported and partial reversal of the cisplatin resistance phenotype was achieved by treatment of the 2008/C13* cells with an antisense oligonucleotide directed against c-fos [20] . Examination of the basal levels of the drug-detoxifying enzyme glutathione S-transferase and the drug transport pump (Multiple drug resistance-associated protein; MRP) revealed no signiWcant diVerence between the parental 2008 and the cisplatinresistant 2008/C13* cells ( [19] and unpublished observations]. All this data indicates that there are multiple mechanisms interconnected in a very complex way producing cisplatin resistance in the 2008/C13* cell line some of which may have clinical relevance. None of these alterations have been shown to be consistently associated with the development of the cisplatin resistance phenotype in tumor cells from diVerent tissue sources. However, the ubiquitous induction of cisplatin and carboplatin resistance in human ovarian, cervical, germ cell and lung carcinoma tumor cells upon forced, constitutive overexpressing of isoforms 1 and 2 of dihydrodiol dehydrogenase [9, 10] was recently demonstrated.
DDH belongs to a superfamily of monomeric, cytosolic NADP(H)-dependent oxidoreductases that catalyze the metabolic reduction and either activation or inactivation of several xenobiotics [26] [27] [28] . In fact, increased expression of a carbonyl reductase has been demonstrated in a doxorubicin resistant tumor cell line [3] . Additionally, increased expression of DDH has been shown in an ethacrynic acidresistant colon carcinoma cell line [8] .
It has been postulated that the mechanism by which DDH induces cisplatin resistance may involve free radicals. In addition to the formation of DNA adducts, cisplatin has been shown to induce oxidative stress in a variety of tumor cells. Also, several diVerent classes of xenobiotics, some of which are known to induce oxidative stress, have been shown to increase the expression of DDH [5] . These observations suggest that DDH induction may be a component of a counter-response to oxidative stress. Thus an investigation as to whether there is an association between DDH and the production of reactive oxygen species (ROS) in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines was undertaken.
Materials and methods

Reagents
Cell culture reagents and gentamycin were obtained from Cellgro (Herndon, Virginia). RNAzol B was purchased from Tel-test Inc. (Friendswood, TX). The enhanced chemiluminescence reagents were from Pierce Biochemicals (Rockford, IL). The antibodies utilized in this study and their suppliers were; rabbit polyclonal HO-2 antibody was from BD Biosciences (San Diego, CA), and the HRPconjugated anti-rabbit antibody was from Pierce Biochemicals (Rockford, IL). Cisplatin was purchased from the Aldrich Chemical Co. (Milwaukee, WI). Methylindoxylacetate (MIA) (1-H-indol-3-ol, 1 methyl-acetate (ester)) was purchased from Sigma (St Louis, MO). H 2 DCFDA was from Molecular Probes (Eugene, OR). All of the components of the RT and the PCR reaction were purchased from Qiagen (Valencia, CA). The primers used in this study were designed using the software program Primer Express, version 1.0 from Applied Biosystems (Foster City, CA). The forward and reverse primer sequence for DDH1, DDH2, DDH3 and DDH4 genes, as well as the Glyceraldehyde-6-phosphate dehydrogenase (GAPDH) gene for routine RT-PCR as well as for real-time RT-PCR analysis is available upon request.
Cell lines
The cisplatin-sensitive and -resistant (2008 and 2008/C13* cells, respectively) human ovarian carcinoma cells were grown in RPMI 1640 medium supplemented with 10% FBS and gentamycin at a Wnal concentration of 10 g/ml as described previously [9, 24] .
Stable overexpression of DDH1, DDH2 or DDH3 in cisplatin-sensitive cells
In order to correlate the function of each isoform of DDH with the cisplatin resistance phenotype, it was necessary to evaluate the eVects of forced overexpression of the recombinant protein produced by each of these genes on anticancer drug cytotoxicity. Thus, primer pairs from the mRNA sequence of each of the candidate genes (using the fulllength sequence data from the sequence deposited in the GenBank database; see [13] ) were designed to enable us to generate a full-length cDNA. These were then cloned into the eukaryotic expression vector (pCDNA4/HisMax-TOPO TA, Invitrogen, San Diego, CA). Orientation of the fulllength cDNA as well as its sequence was determined by restriction enzyme digestion and automated DNA sequencing, respectively. The expression vector with the insert in the right orientation was then transfected into sub-conXuent parental human tumor cell lines using the lipofectamine reagent (GIBCO-Life Sciences) as described previously [9, 24] . The transfected cells were propagated in a medium containing 500-1,000 g/ml geneticin (G418 sulphate) for 3-5 weeks. Individual G418-resistant colonies were picked (20 colonies for each transfection experiment), grown and screened for the expression of the recombinant mRNA utilizing RT-PCR as described below. The clones that expressed a high level of the recombinant message were then subjected to growth inhibition assays in the presence of diVerent concentrations of cisplatin. The cytotoxic eVects of these drugs were assessed using a tetrazolium dye as described previously [9, 24] .
Stable expression of DDH siRNA in cisplatin-resistant cells siRNAs oligonucleotides speciWc for individual DDH isoforms were initially procured from Ambion (Austin, TX). Preliminary experiments demonstrated the eYcacy of individual siRNA oligonucleotides in suppressing the expression of DDH isoforms (data not presented). Thereafter, double stranded oligonucleotides were designed such that these could be cloned into an expression vector for stable knockdown of the corresponding DDH isoform. These were cloned into pSilencer vector (Ambion, Austin, TX) with the neomycin resistance marker gene. siRNA-associated plasmid transfection and generation of stable clones with reduced expression of individual DDH isoforms was carried out as described above. The clones with signiWcant knockdown of the endogenous DDH1 or DDH2 levels were then subjected to growth inhibition assays in the presence of diVerent concentrations of cisplatin. The cytotoxic eVects of these drugs were assessed using a tetrazolium dye as described previously [9, 24] .
In addition, colony formation assays were also performed to assess the cytotoxicity of cisplatin against 2008, 2008/C13*, and 2008/C13* cells transfected with DDH1-siRNA or DDH2-siRNA. 1 £ 10 5 cells of were seeded in 6-well plates and incubated for 24 h and then treated with diVerent concentrations of cisplatin. After a 4 h exposure, the medium was aspirated and the wells were washed in drug-free medium. Cells were trypsinized with 0.25% Trypsin-0.02% EDTA and 100, 200, and 500 cells were seeded in 6-well followed by one week incubation in drugfree complete medium to allow colony formation. At the end of this incubation, medium was aspirated and cells were Wxed and stained with 0.5% (w/v) methylene blue in 50% (v/v) ethanol for 40 min at room temperature. The plates were gently washed with water and allowed to airdry. Visible colonies were counted to determine the percent colony formation after each drug treatment. Values were expressed as the mean § SD from triplicate experiments.
RT-PCR analysis RNA extraction and reverse transcription-PCR were performed essentially as described previously [9, 10] . Each reverse transcription reaction consisted of 1 g of RNA, 4 units of Omniscript RT, 1 M oligo-dT primer, 0.5 mM dNTP, 10 units of RNase inhibitor, and 1£ RT buVer. Reverse transcription was performed at 37°C for 1 h followed by incubation at 93°C for 3 min to inactivate the reverse transcriptase enzyme. Thereafter, equal volume of cDNA was ampliWed by PCR using gene speciWc primer pairs. Each PCR reaction consisted of 1£ PCR buVer, 1.5 mM MgCl 2 , 200 M dNTP, 2.5 units of Taq polymerase, and 0.2 mM gene-speciWc forward and reverse primers. The PCR conditions were as follows; an initial denaturation at 94°C for 3 min, followed by 94°C for 15 s, 55°C (or 57°C for DDH3) for 30 s, 72°C for 30 s for the number of cycles optimized for each primer. A Wnal elongation step was performed for 10 min at 72°C. RT-PCR ampliWcation of GAPDH transcript was used as the internal control to verify that equal amounts of RNA were used from each cell line.
For real-time RT-PCR analysis, SYBR Green dye was utilized in each of the PCR reactions using an Eppendorf Real-Plex PCR system NonspeciWc esterase assay and ROS detection NonspeciWc esterases have been previously reported to be associated with resistance to chemotherapeutic agents, heavy metals, and insecticides [22, 33] . Thus, the activity of nonspeciWc esterases in the cisplatin-sensitive and -resistant human ovarian carcinoma cells was assessed. N-methylindoxyacetate (MIA) was used as a substrate to determine nonspeciWc esterase activity [13] . Fresh stock solutions of 1 mg/ml MIA (5.3 mM) were made weekly in methanol and kept at ¡20°C in the dark. The enzyme activity was measured after 24 h incubation utilizing 4 £ 10 4 cells seeded in 96-well plates. At the end of this time, the growth medium was aspirated and 100 l of warm (37°C water bath-preincubated) HBSS buVer (pH 7.4) and MIA was added to each well and incubated further at 37°C for 30 min. The cells were then washed with warm HBSS twice and the intracellular nonspeciWc esterases activity (that hydrolyzes MIA and result in an increase in Xuorescence) was assessed using a multi-well Xuorescence microplate reader (TECAN GENios) with excitation wavelength set at 405 nm and emission wavelength set at 505 nm.
For estimation of intracellular ROS levels, a cell membrane permeable and oxidant-sensitive Xuorescent dye 5-(6)-chloromethyl-2,7-dichlorodihydroXuorescein diacetate (H 2 DCFDA) was employed [31] . H 2 DCFDA, by itself, is non-Xuorescent, but once inside the cells is hydrolyzed to H 2 DCF by nonspeciWc esterases. The H 2 DCF is an ROSsensitive intermediate whose degradation by intracellular peroxides results in generation of Xuorescent DCF [21] . BrieXy, 4 £ 10 4 cells were seeded in 96-well plates for 24-h incubation. Thereafter, the growth medium was aspirated and 100 l of warm (37°C water bath-preincubated) HBSS buVer (pH 7.4) and H 2 DCFDA was added to each well (Wnal concentration at 25 M) and incubated further at 37°C for 30 min. The cells were then washed with warm HBSS twice and the generation of ROS (measured as Xuorescence intensity) was measured on a multi-well Xuores- /ml and incubated under normal growth conditions for 24 h. Thereafter, the cells were left untreated or treated with cisplatin for the indicated time periods. At the end of each time period, the cells were washed with chilled PBS (3£). The whole cell lysate was prepared from each of the cell line by scraping cells into a buVer containing 20 mM TrisHCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% (v/v) Triton-X-100, 0.5% (v/v) Nonidet P40, 2.5 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 50 mM sodium Xuoride and 1£ protease inhibitor cocktail and incubating on ice for 15 min. Then, the lysate was centrifuged at 13,000g for 20 min and the supernatant was transferred to a fresh tube and stored at ¡80°C until use. Proteins were separated on a SDS-PAG and transferred to a PVDF membrane. Western blotting analysis was performed using rabbit polyclonal antibody against HO-2 (BD Biosciences, San Diego, CA) and enhanced chemiluminescence reagents from Pierce Biochemicals (Rockford, IL).
Statistical analysis
The linear regression analysis and paired t-test were performed using the SigmaStat Statistical Analysis System, Version 1.01. P < 0.05 was considered signiWcant.
Results
Expression of DDH isoforms in 2008 and 2008/C13* cells
RT-PCR analysis was employed to determine the expression levels of the DDH isoforms in cisplatin-sensitive (2008) and cisplatin-resistant (2008/C13*) human ovarian carcinoma cells. The results shown in Fig. 1 indicate that the expression of DDH1, DDH2, and DDH3 was signiWcantly higher in the 2008/C13* cells compared to the 2008 cells. However, expression of DDH4 was not detected in the cisplatin-sensitive or the cisplatin-resistant cells (data not shown). The latter observation was not completely unexpected considering that DDH4 is known to be a liverspeciWc enzyme [25] . Real time RT-PCR analysis was then performed to quantify the diVerential expression of the various DDH isoforms in the cisplatin-sensitive and -resistant cells Table 1 ) were generated that display forced, constitutive 
Cisplatin sensitivity of recombinant clones
The cisplatin sensitivity of the various recombinant clones was assessed and compared to the parental cisplatin-sensitive and -resistant cells utilizing the MTT assay [9, 24] . As shown in Table 2 
Production of ROS and its association with the level of DDH expression
We employed H 2 DCFDA as probe to evaluate intracellular ROS levels in the cisplatin-sensitive and -resistant cells as well as the recombinant clones generated by transfection with either full-length DDH cDNA or the DDH siRNA. Initial results demonstrated that that the cisplatin-sensitive 2008 cells had signiWcantly higher ROS levels compared to the cisplatin-resistant 2008/C13* cells (P < 0.01, Table 3 ).
Forced, constitutive overexpression of DDH1 in 2008 cells (AK6 cells) led to a signiWcant decrease (P < 0.01) in the intracellular ROS levels compared to the 2008 cells (Table 3) To further validate the regulation of intracellular ROS levels by DDH we assessed the ROS levels in the recombinant 2008/C13* clones expressing the DDH1 siRNA or DDH2 siRNA. Transfection of DDH1 siRNA in 2008/C13* cells (8n23 cells) reduced the DDH1 mRNA levels by 78% (as assessed by real-time RT-PCR analysis; data not shown) and a 37% increase in the generation of intracellular ROS was observed in the 8n23 cells (Table 3) . Table 3 The intracellular ROS levels in the cisplatin-senstive andresistant human ovarian carcinoma cells. After incubating the cells overnight the intracellular ROS levels was measured utilizing the Xuorescent probe H 2 DCFDA as described in "Materials and methods" section Similarly, a marked decrease (65%) in the DDH2 mRNA in the 7n1 cells (DDH2 siRNA transfected 2008/C13* cells) was associated with a 63% increase in the intracellular levels of ROS in these cells (see Table 3 ). (Table 4) . Moreover, knockdown of either DDH1 or DDH2 in 2008/C13* utilizing siRNA, resulted in a signiWcant sensitization of the cells to the cytotoxic eVects of t-BHP (Table 4) . Whilst the cytotoxic eVects of H 2 O 2 against 2008/C13* cells with stable knockdown of either DDH1 or DDH2 were decreased (albeit to a lesser extent than to t-BHP), this were found not to be statistically signiWcant. Cellular redox homeostasis is essential for the normal functioning of cellular processes as well as to prevent damage to cellular components including lipids, proteins and nucleic acids. Aberrant production of ROS can lead to cell signaling processes necessary for cellular proliferation as well as those processes that lead to irreversible damage and death. In order to prevent the latter, oxidative stress can induce an adaptive response that activates an antioxidant defense mechanism that facilitates detoxiWcation of ROS and normalizes the redox homeostasis within the cell. Considering that the 2008/C13* cells were generated by step-wise exposure of the parental 2008 cells to increasing concentrations of cisplatin, the upregulation of DDH in the resistant 2008/C13* cells may be an antioxidant defense mechanism responsible for attenuating the intracellular levels of ROS.
In this regard it should be noted that in addition to its direct association with DNA, several recent reports have shown that generation of reactive oxygen species (ROS) upon exposure of tumor cell lines to cisplatin appear to be involved in drug-induced apoptosis. Thus, in human melanoma cells expressing low levels of c-myc, cisplatin treatment increases the generation of ROS, which results in increased apoptosis [4] . Indeed, treatment with cisplatin has been shown to increase the release of intracellular hydrogen peroxide (H 2 O 2 ) as well as superoxide anions in murine macrophage cells [29] . Furthermore, increased resistance to cisplatin has also been observed in Wbroblast cells that are resistant to oxidative stress which was associated with increased catalase activity [30] . In addition, a recent report showed that increased expression of peroxiredoxin II, an enzyme known to eliminate intracellular H 2 O 2 , led to cisplatin cross-resistance in gastric carcinoma cells [7] . Whilst, exposure of the 2008 and 2008/C13* cells to acute cisplatin treatment (1-4 h) did not alter the intracellular ROS levels, we speculate that during the process of development of the cisplatin-resistant subline, the oxidative stress (as a result of cisplatin exposure) led to the increased expression of DDH (adaptive response); a model of cisplatin treatment which mimics the clinical situation, where treatment of short duration (approximately 1-3 h) is repeated up to six or more times over a month or more
The biochemical consequences of increased generation of ROS are many and practically all of these are geared towards rendering the cells unable to divide and proliferate. Thus, (to name a few) increased ROS production leads to DNA strand breakage, activation of caspases and activation of c-jun N-terminal kinases (JNK's) that in turn activate c-jun [12] . In some cases this indicates that ROS commit cells to the process of apoptosis via diverse signaling mechanisms that either work independently or that may have signiWcant cross-talking ability. The fact that overexpression of DDH reduced the basal intracellular levels of ROS and led to development of cisplatin resistance in the 2008/C13* cells, suggests that the apoptotic machinery downstream of ROS has been compromised in the 2008/C13* cells. Indeed, we have demonstrated that the 2008/C13* cells are deWcient in the proteolytic activation of MEKK1 by caspase-3 [11] . This was found to be associated with a lack of activation of JNK and p38MAPK and an increased expression of Bcl-x L in the cisplatin-resistant 2008/C13* cells. Future studies are aimed at elucidating the precise apoptotic pathway that is(are) disrupted due to upregulation of DDH leading to reduced ROS production in the 2008/C13* cells utilizing the various recombinant cell clones generated in this study. 2008 (lanes 1-3) , 2008/C13* (lanes 4-6) and the 8n23 (lanes 7-9) cell lines were seeded at a density of 1 £ 10 6 cells/plate for 24 h. Thereafter, the cells were left untreated (lanes 1, 4, and 7) or treated with 25 mM cisplatin for 1 h (lanes 2, 5, and 8) or 4 h (lanes 3, 6, and  9) . At the end of the time period, the cells were washed with chilled PBS and the whole cell lysate was prepared from each of the cell line by scraping into a buVer containing 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% (v/v) Triton-X-100, 0.5% (v/v) Nonidet P40, 2.5 mM Na pyrophosphate, 1 mM NaOV, 50 mM NaF and 1£ protease inhibitor cocktail and incubated on ice for 15 min. The lysate was then centrifuged at 13,000g for 20 min and the supernatant was transferred to a fresh tube and stored at ¡80°C until use. Proteins (25 g/lane) were separated on a SDS-PAG and transferred to a PVDF membrane. Western blotting analysis was performed using rabbit polyclonal antibody against HO-1 and enhanced chemiluminescence reagents. Expression of -tubulin was evaluated in the same lysates to ensure equal protein concentrations in each sample
